Personalized bloodletting could ease life for iron overload patients
NCT ID NCT04779593
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a blood marker called transferrin saturation to guide bloodletting (removing blood) improves quality of life in people with HFE haemochromatosis, a genetic condition causing iron buildup. 239 adults already on maintenance bloodletting will be randomly assigned to standard care (guided by ferritin alone) or the new approach. Over two years, researchers will track physical health, joint pain, and fatigue using questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bloodletting (phlebotomy)
What this could lead to
If successful, this could lead to a more personalized bloodletting schedule that improves quality of life for people with haemochromatosis.
What could go wrong
This is a mid-stage study with 239 participants, so results may not apply to everyone. The intervention is already standard care, so major breakthroughs are unlikely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOCHROMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Yves le Foll
Saint-Brieuc, France
-
CH de St Malo
St-Malo, France
-
CHR Orléans
Orléans, France
-
CHU Dupuytren
Limoges, France
-
CHU Rennes
Rennes, France
-
Centre hospitalier Bretagne Atlantique
Vannes, France
-
GHBS site du Scorff
Lorient, France
-
GHRMSA - Hôpital Emile Muller
Mulhouse, France
-
Hopital Avicenne
Bobigny, France
-
Hôpital Européen Georges Pompidou
Paris, 75908, France
-
Hôpital Paul Brousse
Villejuif, France
-
Hôpital Rangueil
Toulouse, France